Abbott Laboratories (ABT) has been generating attention due to its solid performance and potential for future growth. The company's portfolio, which contains robust developments, speaks to its strength in the
pharma market. This has driven
institutional investors who now own about 78% of the company's stock. Rumors are revolving around
dividend increases, following a recently declared dividend of
$0.59 per share.
Despite fluctuations in market performance, ABT consistently shows positive returns. Its performance has made
Wall street analysts bullish on the stock, some targeting its price around $130.71. This comes with the signal of
strong financial performance and rising revenues, particularly from their medical devices, resulting in earning beats and raised profit guidance.
However, the company also faces downsides. Recent insider sales have raised eyebrows, potentially signaling perceived weakness. Additionally, there's been a significant drop in their COVID-19 testing revenue. Despite this, the consensus among most
investors and
market experts is that ABT is a strong buy, especially for long-term dividend growth investors.
Abbott Laboratories ABT News Analytics from Wed, 27 Mar 2024 07:00:00 GMT to Sat, 21 Dec 2024 09:31:39 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 7
